OTCPK:LENS.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Presbia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LENS.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-71.2%

LENS.F

0.6%

US Medical Equipment

0.09%

US Market


1 Year Return

-62.7%

LENS.F

14.8%

US Medical Equipment

12.6%

US Market

Return vs Industry: LENS.F underperformed the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: LENS.F underperformed the US Market which returned 13.6% over the past year.


Shareholder returns

LENS.FIndustryMarket
7 Day-71.2%0.6%0.09%
30 Day9.8%0.9%-1.6%
90 Day12.0%11.4%7.9%
1 Year-62.7%-62.7%15.8%14.8%15.2%12.6%
3 Year-99.7%-99.7%72.3%67.9%38.9%29.6%
5 Year-99.8%-99.8%148.2%129.3%87.6%66.5%

Price Volatility Vs. Market

How volatile is Presbia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Presbia undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Presbia is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Presbia has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Presbia's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Presbia regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Presbia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Presbia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Presbia performed over the past 5 years?

15.4%

Historical Healthcare annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if LENS.F has high quality earnings.

Growing Profit Margin: Insufficient data to determine if LENS.F's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LENS.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare LENS.F's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if LENS.F's earnings growth over the past year exceeded the Medical Equipment industry average.


Return on Equity

High ROE: LENS.F has a negative Return on Equity (0%), as it is currently unprofitable.


Next Steps

Financial Health

How is Presbia's financial position?


Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if LENS.F's short term assets cover its short term liabilities.

Long Term Liabilities: LENS.F has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LENS.F is debt free.

Reducing Debt: LENS.F currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: LENS.F has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: LENS.F has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Presbia current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LENS.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LENS.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LENS.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LENS.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LENS.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average board tenure


CEO

Zohar Loshitzer (63 yo)

1.33yrs

Tenure

Mr. Zohar Loshitzer serves as Director at Ossio Inc. He serves as Executive Chairman of the Board and Chief Executive Officer at Presbia PLC since May 01, 2019. Mr. Loshitzer serves as a Principal at Orcha ...


CEO Compensation Analysis

Compensation vs Market: Zohar's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: Insufficient data to compare Zohar's compensation with company performance.


Board Members

NamePositionTenureCompensationOwnership
Zohar Loshitzer
Executive Chairman & CEO1.33yrsno data2.37%
$ 4.6k
Kerry Assil
Member of Medical Advisory Boardno datano datano data
Richard Ressler
Director5.67yrsno data24.87%
$ 47.9k
Mark Blumenkranz
Member of Medical Advisory Board5.08yrsUS$115.96kno data
Ioannis Pallikaris
Chairman of Medical Advisory Boardno datano datano data
Michael Gordon
Member of Medical Advisory Boardno datano datano data
Ronald Krueger
Member of Medical Advisory Boardno datano datano data
Marco Fantozzi
Member of Medical Advisory Boardno datano datano data

5.1yrs

Average Tenure

63yo

Average Age

Experienced Board: LENS.F's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Presbia PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Presbia PLC
  • Ticker: LENS.F
  • Exchange: OTCPK
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$192.496k
  • Shares outstanding: 17.19m
  • Website: https://www.presbia.com

Number of Employees


Location

  • Presbia PLC
  • Sandyford Office Centre
  • Suite 7
  • Dublin
  • 18
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LENS.FOTCPK (Pink Sheets LLC)YesNew Ordinary SharesUSUSDJan 2015

Biography

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for pro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 06:36
End of Day Share Price2020/09/16 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.